SPOTLIGHT -
The Latest in the Hepatitis B Drug Pipeline
Why cost and treatment length are some of the biggest concerns for drug manufacturers.
Read More
Peptic Ulcer Disease Drug Pipeline: What You Need to Know
The current and future treatments for the $10 billion condition.
Eight Top Oncology Drug Approvals
New cancer drugs continue to offer patients hope. Here are eight of them.
Oncology Pipeline Predictions
This year has been another year full of oncology approvals, proving that the oncology pipeline is robust with first-of-the kind molecules, competitor products for existing agents, and biosimilars.
How Tweaking Therapies Can Help Mental Health Treatment
Not all therapies work the same in every patient, but that’s not the biggest challenge in treating mental health. This is.
Three Vaccine Developments Healthcare Execs Should Watch
Vaccines are an important part of creating “herd immunity” to keep infectious diseases in check. Here are three vaccine developments that have far reaching implications for public health.
Top Advancements in Lung Cancer: What Health Execs Should be Watching
Oncology experts shed light on progress of genetic testing and targeted therapies in lung cancer.
HIV Pipeline Prospects Getting Healthier
There is no cure for HIV, but with proper medical treatment, the disease can be controlled.
Groundbreaking gene therapies in store for hemophilia
Treatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
Autoimmune drug pipeline highlights
More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
Oncology treatments: Three areas to watch
While targeted cancer therapies make up a big part of the pipeline, there are three areas that oncology experts want you to keep on your radar.
Pediatric drug market poised for growth
More support for clinical trials and a wider lens for rare diseases in children sets the category on fire.
Oral specialty drug options on the horizon
As more specialty drugs are approved, cost control strategies are key.
Brace for a barrage of biosimilars
The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
Popular insulin meets target in real-world study
Novo Nordisk’s DEVOTE study reveals interesting findings.
New universal companion diagnostic paves the way for precision oncology
FDA approves new diagnostic test for non-small cell lung cancer.
New antibiotic approved for acute bacterial skin infections
FDA approved the use of a new fluoroquinolone antibiotic to treat ABSSSI.
Evolving hepatitis C pipeline offers hope to patients
Cost burden prompts payers to consider appropriate utilization
FDA to drug maker: Pull opioid pain drug
Potential public health consquences prompts FDA to request removal of opioid pain medication.
FDA approves EpiPen rival
Adamis’ epinephrine injection promises to be a lower-cost alterative to EpiPen.
FDA approves first generic Truvada for HIV
The first generic Truvada for treating and preventing HIV will be available, but when?
FDA gives once-daily HIV therapy go-ahead
FDA approves Isentress at a higher dose for HIV-1 infected patients.
Asthma biologic may reduce oral steroid use
A new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.
First generic Strattera for ADHD approved
FDA has approved the first generic versions of Strattera (atomoxetine) for the treatment of attention deficit/hyperactivity disorder.
Pharmaceutical pipeline: Top 4 conditions to watch
Although drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
Investigational drug appears beneficial in preventing migraines
Lilly's galcanezumab proves successful in three phase 3 migraine studies. Here are the findings.
Drugmaker recalls samples of antiplatelet drug
AstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
Combination pack approved for breast cancer treatment
FDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.
Top 5 specialty drug management issues
The 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.
How pharma reps impact physician prescribing
A new study led by The University of California researchers and published in JAMA reveals surprising findings.